1-(4-fluoro-phenyl)-3-(R)-[3-(2-methoxy-ethyl)-2-oxo-oxazolidin-5-ylmethyl]-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one | 1218940-82-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-fluoro-phenyl)-3-(R)-[3-(2-methoxy-ethyl)-2-oxo-oxazolidin-5-ylmethyl]-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
• 英文别名: (5R)-5-[[1-(4-fluorophenyl)-8-[(8-methylnaphthalen-1-yl)methyl]-4-oxo-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]-3-(2-methoxyethyl)-1,3-oxazolidin-2-one
• CAS: 1218940-82-9
• 化学式: C₃₂H₃₇FN₄O₄
• 分子量: 560.669
• InChiKey: QDKDSMQCRDIIHR-NDEPHWFRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  41
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  65.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-3-(R)-(2-oxo-oxazolidin-5-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one 、 2-溴乙基甲基醚 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 0.83h， 生成 1-(4-fluoro-phenyl)-3-(R)-[3-(2-methoxy-ethyl)-2-oxo-oxazolidin-5-ylmethyl]-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
  参考文献：
  名称：

  US2010/76003

  摘要：

  公开号：

文献信息

• 5-OXAZOLIDIN-2-ONE SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS
  申请人：BATTISTA Kathleen

  公开号：US20100076003A1

  公开（公告）日：2010-03-25

  The present invention is directed to novel 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful in the treatment of disorders and conditions mediated by the ORL-1 receptor. The present invention is further directed to processes for the preparation of said derivatives, pharmaceutical compositions comprising said derivatives and methods for the treatment of ORL-1 mediated disorders and conditions.
• [EN] 5-OXAZOLIDIN-2-ONE SUBSTITUTED 1,3,8-TRIAZASPIRO [4.5] DECAN-4-ONE DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE 1,3,8-TRIAZASPIRO[4.5]DÉCAN-4-ONE SUBSTITUÉS PAR DE LA 5-OXAZOLIDIN-2-ONE UTILISABLES EN TANT QUE MODULATEURS DU RÉCEPTEUR ORL-1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010033451A2

  公开（公告）日：2010-03-25

  The present invention is directed to novel 5-oxazolidin-2-one substituted 1,3,8-thazaspiro[4.5]decan-4-one derivatives useful in the treatment of disorders and conditions mediated by the ORL-1 receptor. The present invention is further directed to processes for the preparation of said derivatives, pharmaceutical compositions comprising said derivatives and methods for the treatment of ORL-1 mediated disorders and conditions.